TriLink to Open New GMP Facility Aimed at Early Phase Therapeutic Manufacturing

TriLink BioTechnologies announced their new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014. TriLink’s new facility will feature validated ISO Class 7 and ISO Class 8 clean rooms, specifically designed to facilitate fast turnaround of IND-enabling tox and Phase 0/I GMP material. The company is a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA.

CEO Richard Hogrefe commented:

Our existing quality system, agile business model and extensive nucleic acid synthesis experience place us in a prime position to provide affordable IND and Phase I materials fast. We hope this new service provides an avenue for more nucleic acid based drugs to make it to the clinic.

Click here to view the full press release.